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Introduction: Agitation is a major problem in acute schizophrenia.
Only a few studies have tested antipsychotic agents in severely agitated
patients, mainly because of legal issues. Furthermore, most studies were
limited to the first 24 hours. We aimed to investigate the efficacy of oral
haloperidol, risperidone, and olanzapine in reducing psychotic agitation
in severely agitated patients with schizophrenia or schizophreniform or
schizoaffective disorder over 96 hours using a prospective, randomized,
rater-blinded, controlled design within a naturalistic treatment regimen.
Methods: In total, 43 severely agitated patients at acute care psychi-
atric units were enrolled. Participants were randomly assigned to receive
either daily haloperidol 15 mg, olanzapine 20 mg, or risperidone 2 to
6 mg over 5 days. Positive and Negative Syndrome Scale psychotic agi-
tation subscale score was the primary outcome variable. A mixed-model
analysis was applied.
Results: All drugs were effective for rapid tranquilization within 2 hours.
Over 5 days, the course differed between agents (P G 0.001), but none
was superior. Dropouts occurred only in the risperidone and olanzapine
groups. Men responded better to treatment than did women during the
initial 2 hours (P = 0.046) as well as over the 5-day course (P G 0.001).
No difference between drug groups was observed regarding diazepam or
biperiden use.
Conclusions: Oral haloperidol, risperidone, and olanzapine seem to
be suitable for treating acute severe psychotic agitation in schizophrenia
spectrum disorders. Response to oral antipsychotics demonstrated a gender
effect with poorer outcome in women throughout the study.
Key Words: aggressive behavior, agitation, schizophrenia, rapid
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(J Clin Psychopharmacol 2014;34: 124Y128)
Aggression and agitation are frequent problems during acuteschizophrenia episodes.1,2 Aggressive behavior in inpatient
settings is associated with involuntary admission and schizo-
phrenia diagnosis.3Y5 Interestingly, some studies reported women
to exert more aggressive behavior during the acute inpatient treat-
ment than men.5,6
Both agitation and aggressive behavior represent psychi-
atric emergencies requiring rapid intervention to prevent harm
to the patient, staff, or other subjects. A number of nonpharma-
cological interventions have been suggested, such as talking
down or clearing the room of other patients.7 Pharmacological
treatment of agitation and aggression in schizophrenia should
aim at calming the patient while treating the underlying psy-
chosis.1,2 Therefore, clinical guidelines recommend parenteral
administration of typical antipsychotics in combination with
benzodiazepines as the first line for rapid tranquilization.8,9
In addition to parenteral antipsychotics, oral administration of
second-generation antipsychotics has proven efficacious in re-
ducing acute agitation, as has been reported for risperidone,
olanzapine, aripiprazole, and quetiapine.10Y15Most previous studies
on acute agitation in mixed patient populations report outcomes
only in the first 24 to 72 hours after admission,12,13,15Y17 and only
a few studies extend over 5 days.11,14 However, efficacy of anti-
psychotic agents may vary widely over an observation period,
with some exhibiting superior performance only during the initial
hours.11,13 Despite this, we are unaware of any trials comparing
oral formulations of first- and second-generation antipsychotics
beyond the first day in acutely agitated schizophrenia patients.
Furthermore, interventional trials must obtain prior informed con-
sent from study participants, precluding prospective studies in
severely agitated or aggressive patients. Thus, most studies on
pharmacotherapy of acute schizophrenia episodes have been
conducted in patients with low agitation scores.
In the current study, we try to overcome these 2 problems
by investigating the effects of 3 oral antipsychotics (haloperidol,
olanzapine, and risperidone) on psychotic agitation in severely
agitated patients with schizophrenia spectrum disorders during
the first 5 days after admission and obtaining informed consent
for inclusion in the study after remission of the psychotic epi-
sode. The study was a prospective, randomized, rater-blinded
trial in a naturalistic treatment setting and regimen. Based on
independently reported results in the literature, we hypothesized
superior performance of olanzapine and haloperidol during the
initial 2 hours, as well as a reduced need for additional benzo-
diazepines with olanzapine administration. In addition, because
of reported diminished effect of antipsychotics in women, we
examined gender effects on treatment response.
PATIENTS AND METHODS
Participants
From February 2004 until September 2005, all patients ad-
mitted to the acute care inpatient units of the University Hospital
of Psychiatry Bern, Switzerland, were screened for schizophrenia,
schizoaffective, or schizophreniform disorder according to the
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Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition criteria. Diagnoses were made based on psychiatric ex-
amination and review of all case files. Only subjects aged between
18 and 55 years were further evaluated. Subjects with relevant
medical or neurological disorders, whowere pregnant, or who had
ongoing intake of illicit drugs and alcohol were excluded.
Assessments
Symptom severity was assessed using the Positive and
Negative Syndrome Scale (PANSS).18 We used the PANSS psy-
chotic agitation subscale (PANSS-PAS) including PANSS items
hallucinatory behavior (P3), excitement (P4), hostility (P7), un-
cooperativeness (G8), and poor impulse control (G14) to select
subjects who were highly agitated. The PANSS-PAS was used
in previous studies10 and is similar to the PANSS excitement
subscale used in comparable studies on agitation,19,20 with a
range of 5 to 35 points. Further assessments included the Ab-
normal Involuntary Movement Scale (AIMS),21 the Simpson
Angus Scale for Parkinsonism (SAS),22 and the Barnes Akathisia
Rating Scale (BARS).23
Procedures
Subjects scoring 20 (eg, moderate symptom severity in
each of the 5 items) or higher on the PANSS-PAS were ran-
domly assigned to 1 of the 3 treatment regimens. As it was not
possible to obtain informed consent at the time of study inclu-
sion due to severe agitation, an independent psychiatric con-
sultant had to clinically confirm whether the study criteria were
met. Randomized treatment allocation was permitted since the
protocol strictly followed the Swiss registration guidelines for
antipsychotics, and none of the 3 oral substances has proven
superiority in treating agitation. After remission of the acute
symptoms and regaining the capacity to understand the study
procedures, subjects were asked for written consent to partici-
pate in the study. Only data from participants who provided post
hoc consent were included in study analyses (see Figure S1,
Supplemental Digital Content 1, http://links.lww.com/JCP/A218).
This approach is in line with the World Medical Association
Declaration of Helsinki. The local ethics committee approved
the study protocol.
In total, 6 study visits were conducted over a total of
5 days. On day 1, 2 visits occurred: at baseline (T0) and 2 hours
later (T1). Additional visits randomly took place within 24 hours
(T2), 48 hours (T3), 72 hours (T4), and 96 hours (T5) after
baseline. The PANSS-PAS was assessed at each visit, and the
complete PANSSwas evaluated at T0 and T5. The AIMS, BARS,
and SAS were rated at T5. All ratings were performed by 1 of
2 raters who were blind to treatment allocation, had received
PANSS training, and had no access to the randomization proto-
col. Randomization was performed by creating 3 sets of random
numbers between 1 and 60 using a computer-based research
randomizer (www.randomizer.org). The order of inclusion de-
termined allocation to treatment group. The randomization list
was locked in the office of the principal investigator (T.J.M.),
who was engaged neither in treatment nor in study assessments.
Swiss registration guidelines on antipsychotic administra-
tion were strictly adhered to as follows: on the first day, 10 mg
haloperidol, 2 mg risperidone, or 15 mg olanzapine were ad-
ministered as regular tablets. The additional use of up to 30 mg
diazepam was permitted. From days 2 through 5, fixed doses of
haloperidol (7.5 mg twice daily [BID]) and olanzapine (20 mg)
were given, whereas risperidone doses were 2 mg BID on day 2
and 3 mg BID on day 3. Subsequently, risperidone doses could
be increased by 1 mg/d at the discretion of the independent
psychiatric consultant. The additional use of up to 60 mg diazepam
was permitted from days 2 through 5. In case the additional medi-
cation was not sufficient to control agitation, subjects received
higher doses of parenteral typical antipsychotics and diazepam and
were considered dropped from the study because of lack of efficacy.
Statistical Analyses
Analyses were based on the intent-to-treat model. W2 Tests
for categorical data and analysis of variance for continuous data
were computed to compare baseline characteristics between the
3 medication groups. Courses of tranquilization from T0 to T5
were analyzed by a mixed model of repeated measures with
PANSS-PAS as the primary outcome, time as the random factor,
and type of medication as the fixed factor. Total dose of diaz-
epam and total dose of biperiden prescribed during the obser-
vation period (T0YT5) were included as covariates to statistically
control their effect on psychotic agitation. Main (time and medi-
cation) and interaction (timemedication, time diazepam, and
time biperiden) effects were tested. Rapid tranquilization within
2 hours was analyzed by an analysis of covariance (ANCOVA)
with the same variables as used in the mixed model but only for
the 2 assessments within the first day. Again, main and interaction
effects were tested. Finally, the same analyses for rapid and course
of tranquilization were performed, with gender as the fixed factor.
Other outcome variables were compared using analyses of vari-
ance or W2 tests. For these other outcome variables, the last ob-
servation carried forward method was applied to data of patients
who were prematurely dropped from the study. All analyses were
computed with the Statistical Package for the Social Sciences
(SPSS 19; SPSS Inc, Chicago, IL).
RESULTS
In total, 52 subjects were eligible for inclusion. Post hoc
consent was provided by 43 subjects (83%), whose data were
included in the analyses. The final analyses included 14 subjects
on haloperidol, 15 on olanzapine, and 14 on risperidone. The
groups did not differ in clinical or demographic variables. Patients
were predominantly male (72%). Eleven had immigrant status.
Diagnoses included paranoid (n = 18), disorganized (n = 5), cat-
atonic (n = 1), and residual (n = 3) schizophrenia, as well as
schizophreniform (n = 10) and schizoaffective (n = 6) disorder.
Mean age was 34.4 (SD, 10.1) years, duration of illness was 6.9
(SD, 6.6) years, and duration of education was 11.6 (SD, 2.5)
years. Before admission, 4 participants had consumed alcohol,
and 5 have used cannabis. The average PANSS scores were as
follows: positive, 36.1 (SD, 5.2); negative, 25.5 (SD, 8.4); PAS,
26.4 (SD, 3.4); EC, 28.0 (SD, 4.1); and total score, 126.7 (SD, 16.9).
Of the 43 subjects, 36 (83.7%) were free of antipsychotics
or mood stabilizers at the time of study inclusion with no differ-
ences between the 3 treatment groups. Whereas the olanzapine
and haloperidol groups received a fixed dose, the risperidone
group received varying antipsychotic dosage after the first day.
Mean daily risperidone doses were the following: day 2: 3.7 (SD,
1.1) mg; day 3: 5.5 (SD, 1.7) mg; day 4: 5.5 (SD, 1.7) mg; day 5:
5.5 (SD, 1.7) mg. Six subjects (13.9%) were dropped from the
study because of lack of efficacy. Of those who were dropped,
4 subjects were on risperidone (2 on day 1, 1 on day 3, 1 on day 5),
and 2 were on olanzapine (1 on day 1 and 1 on day 5).
PANSS-PAS Scores
Rapid tranquilization effects were analyzed for the first
2 hours (see Table S1, Supplemental Digital Content 2,
http://links.lww.com/JCP/A219). The PANSS-PAS scores im-
proved with any medication, as we noted an effect of time (P G
0.001), but neither effect of medication nor a time  medica-
tion interaction. Furthermore, the administration of diazepam
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or biperiden did not affect the effects of antipsychotic medica-
tion on PANSS-PAS. Moreover, we noted a gender effect (P =
0.046) indicating that men responded better to treatment than did
women in the first 2 hours.
Regarding the PANSS-PAS score over the 5-day course of
the study, we observed a significant effect of time (P G 0.001)
as well as a significant medication  time interaction (P G
0.001; Fig. 1). Post hoc ANCOVAs with gender and diazepam
and biperiden cumulative doses as covariates indicated signifi-
cant differences between antipsychotics at T3 (P = 0.009) and
T4 (P = 0.031), as well as trends for T1 (P = 0.053), T2 (P =
0.092), and T5 (P = 0.074), without significant differences in
the single substance contrasts at any time point. Furthermore,
in the mixed model, PANSS-PAS scores were affected by the
interaction of gender  time (P G 0.001), demonstrating that
women never improved as much as men (see Figure S2, Sup-
plemental Digital Content 3, http://links.lww.com/JCP/A220).
No other effect was significant, including factors such as anti-
psychotic drug, diazepam, biperiden, and their interaction terms
with time. Post hoc ANCOVAs with antipsychotic drug, diaze-
pam, and biperiden cumulative doses as covariates indicated sig-
nificantly less PANSS-PAS reduction in women at T1 (P = 0.046),
T3 (P = 0.004), and T4 (P = 0.020), as well as a trend at T2
(P = 0.056). Adding the duration of illness as a covariate did not
change the results of these primary analyses (data not shown).
Additional Outcome Measures
Possible motor adverse effects did not differ between
groups at T5 in scores of BARS, SAS, and AIMS. Further-
more, the use of additional medication was not different be-
tween groups (see Table S2, Supplemental Digital Content 4,
http://links.lww.com/JCP/A221). Comparing the PANSS-EC at
T0 and T5, we found a significant effect of time (P G 0.001), but
no effect of antipsychotic agent and no interaction effect. Results
did not change after controlling for diazepam administration.
Diazepam was administered to 37 subjects (86%) within the
first 24 hours. The mean cumulative dose for the first 24 hours
was 25.6 (SD, 17.0) mg, with no difference between groups.
During the study period, severe agitation led to use of seclusion
in 2 subjects (1 on haloperidol and 1 on olanzapine) and to the
use of physical restraints in 9 subjects (2 on haloperidol, 4 on
risperidone, and 3 on olanzapine).
DISCUSSION
In the present study, oral administration of haloperidol,
olanzapine, or risperidone was highly effective in reducing psy-
chotic agitation in schizophrenia within 2 hours. The course
over 5 days differed between antipsychotic substances used, but
post hoc analyses favored none of the agents. Interestingly, men
responded better to treatment than did women throughout the
course of the study.
Our findings regarding the rapid tranquilization in severely
agitated schizophrenia are in line with previously published
work.10Y13 Most studies have reported no differences between
substances in the first 2 hours after administration.11Y13 Re-
cently, Hsu et al13 noted a superior performance of olanzapine
over haloperidol during the first 90 minutes; however, they found
no differences in the efficacy of haloperidol intramuscularly
(IM), olanzapine IM, olanzapine oral disintegrating tablets, and
risperidone oral solution after 24 hours. The slight difference
to the study of Hsu et al,13 which found superior effects for
olanzapine only in the first 90 minutes, may stem from the par-
ticipant selection. Even though the PANSS-EC scores indicate
comparable symptom severity, the trial of Hsu et al13 included
patients with bipolar I disorder (43%). Taken together, rapid
tranquilization in acutely agitated schizophrenia patients may
be achieved by any of the tested antipsychotics even when ad-
ministered orally. However, it remains unclear whether PANSS-
PAS reduction within the first 2 hours is achieved by specific
antipsychotic action or by sedative properties of antipsychotic
substances. Use of additional diazepam was frequent and not
different between groups.
Even though all 3 agents effectively reduced agitation over
5 days, the course differed between groups, particularly at days
3 and 4. However, the post hoc tests did not reveal a significant
difference between the agents at any time point. Two controlled
trials over 5 days also reported no difference between oral
aripiprazole and oral olanzapine14 and between oral risperidone
and intramuscular haloperidol.11 Likewise, an observational,
nonrandomized study in a mixed psychiatric emergency popu-
lation failed to find differences between olanzapine, risperi-
done, and haloperidol over 5 days.24 In contrast, longer trials
seem to favor olanzapine. A 3-year observational study docu-
mented lesser violence in patients on olanzapine maintenance
than in risperidone-treated patients.25 Likewise, post hoc anal-
yses from larger 6-week trials indicated superior improvement
of psychotic agitation with oral olanzapine compared with oral
haloperidol.26 We noted differences between substances over a
5-day course of treatment, but the variance is not systematically
related to a single antipsychotic agent.
With both second-generation antipsychotics, subjects were
dropped from the study because of lack of efficacy. Four drop-
outs were in the risperidone group and 2 in the olanzapine
group. One explanation could be that the dose regimen of ris-
peridone included rather low doses on the first and second days.
Although the present study followed the Swiss registration
guidelines, it is conceivable that the outcome was dependent on
the dosages used. The haloperidol doses used in other trials
were lower for oral formulations (range, 10Y15 mg/d)15 and in
the same range for IM formulations (range, 5Y20 mg/d).10Y13
The olanzapine dosage used was comparable to that used in
other trials (range, 10Y20 mg/d),13Y15,27 whereas the risperidone
dosage in the first 2 days was lower than the dose in other trials
(range, 2Y6 mg).11Y13 Thus, the dose regimen applied in this study
may have contributed to better performance of haloperidol in
FIGURE 1. Agitation scores. Mean and SEM of PANSS-PAS scores
are depicted. Solid line: haloperidol, dashed line: risperidone,
dotted line: olanzapine.
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terms of the number of subjects dropped from the study. The
frequency of seclusion or physical restraints, however, did not
differ between the groups.
In the present study, we observed a gender effect indicating
that women did not respond to antipsychotic treatment as well
as men did. Differences between genders were noted consistently
from the first rating after baseline (2 hours) until T4 (3 days).
Thus, throughout the initial 72 hours, men showed more favor-
able outcomes. The gender difference in aggressive behavior
is increasingly acknowledged. Women displayed proportionally
more aggressive behavior than did men in the initial 4 weeks of
inpatient treatment,5,6,28 whereas during longer hospitalization
this difference disappears.4,6 This gender effect of the early in-
patient period could contribute to the poor treatment response in
women observed in our study. Furthermore, men might be more
compliant in these emergencies. When given the choice of oral
versus IM medication, men chose oral medication during severe
agitation more frequently than did women.10 To the contrary, a
study reported pronounced reductions of assaults with treat-
ment in women compared with men,6 linking positive symp-
tom severity and aggression, particularly in women. However,
this study compared treatment efficacy between groups after
4 weeks.
This study design limited the selection bias due to a refusal
to participate in the acute psychotic state. Nonetheless, 17% of
the patients initially randomized declined post hoc consent for
study inclusion. We have, however, included a representative
portion of the highly agitated psychotic patients admitted to our
department. This is a clear strength of the study. The severity of
agitation as measured with the PANSS-EC is in the same range as
reported in 1 controlled trial and 3 observational studies10,13,24,27
but clearly higher than in most controlled trials.11,12,14 We have
used higher PANSS cutoff scores for inclusion than the cutoff
used in most other studies.11Y13,20 Furthermore, we restricted our
sample to schizophrenia spectrum disorders, excluding patients
with bipolar disorder who represent a considerable proportion in
some trials.12,13,27
The main limitation of this study is the limited number of
participants, which is not sufficient to support noninferiority
conclusions of 1 of the antipsychotic agents used. Furthermore,
the acute and agitated presentation at baseline prevented us
from conducting comprehensive assessments of psychosocial
function or pretreatment motor disorders. Therefore, we cannot
comment on treatment-emergent motor adverse effects. Fur-
thermore, there is a potential risk of diagnostic bias as the di-
agnoses were not established in structured interviews, mainly
because of time limitations at inclusion. As discussed above, a
change in dose regimen may have resulted in slightly different
effects, as the initial risperidone dose is lower than that used in
other trials.11Y13
Oral administration of haloperidol 10 mg, olanzapine 15 mg,
or risperidone 2 mg was highly effective in reducing psychotic
agitation in patients with schizophrenia spectrum disorders within
2 hours. These agents differed in the effect on agitation over the
5-day course. Women were less responsive to treatment than
men within the first 72 hours. Our results do not favor 1 of the
oral antipsychotics for acute agitation in schizophrenia, which
might be a result of the small sample size.
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